Austin, Texas, USA – May 21, 2026
Natera, Inc., a global leader in cell-free DNA testing and precision medicine, announced a major expansion of its operations in Austin, Texas, including plans to create what is believed to be the largest sequencing facility in the world. The company revealed that the expansion will significantly increase sequencing capacity while supporting rapid growth in oncology diagnostics, personalized medicine, and molecular residual disease testing. The new development includes a dedicated sequencing facility and additional operational space within a second building at Natera’s North Austin headquarters campus. The expansion comes as demand for advanced genomic testing solutions continues rising across cancer diagnostics, women’s health, and organ health markets worldwide.
Natera stated that the new facility will support increasing demand for its testing solutions, particularly in oncology, where year-over-year testing volumes increased by more than 54% during the first quarter of 2026. The company’s flagship Signatera™ molecular residual disease test has become one of the most widely adopted precision oncology tools in the United States and is currently used by more than 50% of U.S. oncologists. Recently, Signatera™ CDx also became the first FDA-approved companion diagnostic for molecular residual disease testing, further strengthening Natera’s position in personalized cancer diagnostics.
Natera Expands Sequencing Infrastructure for Precision Medicine
The Austin expansion reflects growing global demand for advanced genomic sequencing technologies capable of supporting large-scale precision medicine applications. Natera explained that the dedicated sequencing facility will dramatically increase laboratory throughput and operational scalability, enabling the company to process larger testing volumes while accelerating turnaround times for clinicians and patients. Industry analysts believe the expansion positions Natera among the leading genomic diagnostics companies worldwide as healthcare systems increasingly integrate molecular testing into standard clinical care.
Natera executives stated that the company remains heavily focused on expanding personalized diagnostics for oncology and other serious diseases. The company’s technologies use cell-free DNA (cfDNA) to identify cancer recurrence, monitor treatment response, detect genetic abnormalities, and guide personalized therapeutic decisions. These tests are increasingly being used to support earlier intervention strategies and precision treatment planning in cancer care.
Advertisement
According to company leadership, the additional laboratory space and sequencing infrastructure will help support both clinical operations and ongoing research initiatives. Natera currently participates in hundreds of clinical trials and research collaborations designed to expand the evidence supporting personalized diagnostics and next-generation genomic testing technologies. The company emphasized that large-scale sequencing capabilities are essential for driving innovation in precision medicine and improving long-term patient outcomes.
Signatera Continues Driving Oncology Testing Growth
Natera’s Signatera platform has emerged as one of the most important tools in the growing molecular residual disease (MRD) testing market. The personalized assay is designed to detect residual cancer DNA in blood samples following treatment, helping clinicians identify recurrence risk earlier than conventional imaging or diagnostic approaches. Researchers believe MRD testing may significantly improve cancer monitoring strategies by enabling faster therapeutic interventions and more individualized treatment planning.
The rapid adoption of Signatera among oncologists has fueled substantial growth in Natera’s oncology business segment. Company executives noted that precision oncology remains one of the fastest-growing areas within healthcare diagnostics due to increasing demand for biomarker-driven treatment strategies and personalized monitoring technologies. The FDA approval of Signatera CDx is also expected to accelerate broader clinical adoption and reimbursement opportunities in the United States and global markets.
Natera additionally confirmed that the Austin expansion is expected to generate up to 400 new jobs across professional, laboratory, scientific, and operational functions. The company stated that workforce growth will support expanding laboratory operations, research programs, software systems, and clinical support infrastructure as demand for precision diagnostics continues rising worldwide.
Precision Diagnostics Industry Continues Rapid Expansion
The precision medicine and genomic diagnostics sector has experienced substantial growth over the past decade as healthcare providers increasingly adopt molecular testing to improve clinical decision-making. Advances in sequencing technologies, bioinformatics, and artificial intelligence are helping diagnostic companies process larger genomic datasets with greater speed and accuracy. Industry experts believe large-scale sequencing infrastructure investments will become increasingly important as genomic medicine expands into mainstream healthcare delivery.
Natera currently operates ISO 13485-certified and CAP-accredited laboratories under Clinical Laboratory Improvement Amendments (CLIA) standards in Austin, Texas, San Carlos, California, and Boulder, Colorado through its subsidiary Foresight Diagnostics. Analysts expect the company’s new sequencing facility to further strengthen its global leadership position within precision oncology and personalized genetic testing markets.
As precision medicine continues transforming cancer care and diagnostic workflows worldwide, Natera’s expansion underscores the growing importance of scalable genomic sequencing infrastructure in supporting the future of personalized healthcare and molecular diagnostics innovation.
Source: Natera press release
